VRTX CHMP opinion: Thursday, July 23, 2026
Variation type II · Kaftrio · Update of section 5.1 of the SmPC in order to introduce newly tested ELX/TEZ/IVA-responsive FRT mutations, based on results from the nonclinical study report U032 version 3.0; this is an in vitro pharmacological profiling of cystic fibrosis transmembrane conductance reg
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.